International Journal of Healthcare Sciences ISSN 2348-5728 (Online)
Vol. 5, Issue 2, pp: (522-528), Month: October 2017 - March 2018, Available at: www.researchpublish.com

Overview Etiology and Management of Liver Cirrhosis

[1]Zeyad Saad Aljohani, [2]Hisham Mohammed Almuwallad, [3]Ahmed Suhail Maimani, [4]Faisal Ali Ibrahim Alghamdi, [5]Omar Abdullah Basfar, [6]Abdulaziz Abdullah Saeed Al Nahdi, [7]Abdulmalick Mohammed Zaheralliyali, [8]Mustafa Mohammad Ayyad

Abstract: **In this review we will discuss background and etiology of liver cirrhosis, we will emphasize diagnostic methods and management, such as transplantation and lifestyle modification. We conducted an electronic literature search of MEDLINE, EMBASE, and Cochrane Library databases, until December 2017. We used the search Mesh terms: liver cirrhosis, *management, etiology, causes, treatment*. ALD remains a significant cause of liver related mortality worldwide. Clinicians ought to be experienceded on the diagnosis and treatment of the broad spectrum of hepatologic conditions related to ethanol consumption. Combined with the 2010 AASLD/ACG guidelines on the treatment of serious alcoholic hepatitis, PTX needs to be considered an alternative to corticosteroids and shows up to especially efficient in ALD patients with renal dysfunction/hepatorenal syndrome. Cirrhosis frequently is an indolent disease; most patients continue to be asymptomatic up until the occurrence of decompensation, defined by ascites, spontaneous bacterial peritonitis, hepatic encephalopathy, or variceal bleeding from portal hypertension. Physical examination of patients with cirrhosis may expose a variety of findings that require a hepatic- or gastrointestinal-based work-up to identify the etiology.**

Keywords: **liver cirrhosis, chronic, or durable, injury.**

1. INTRODUCTION

Cirrhosis is a problem in which the liver slowly degrades and is incapable to function normally because of chronic, or durable, injury. Scar tissue changes healthy liver tissue and partly blocks the flow of blood through the liver. The liver is the body's largest inner body organ. The liver is called the body's metabolic factory as a result of the crucial duty it plays in metabolism-- the means cells transform food into energy after food is absorbed and soaked up into the blood. A healthy and balanced liver is needed for survival [1] The liver can regrow the majority of its very own cells when they become damaged. Nonetheless, if injury to the liver is as well severe or long-term, regeneration is insufficient, and the liver develops scar tissue. Scarring of the liver, likewise called fibrosis, could bring about cirrhosis. The buildup of scar tissue that creates cirrhosis is usually a slow-moving and steady process. In the onset of cirrhosis, the liver continuouslies function. Nonetheless, as cirrhosis gets worse and mark tissue replaces much more healthy tissue, the liver will certainly begin to fail [2].Chronic liver failing, which is additionally called end-stage liver illness, advances over months, years, or perhaps decades. With end-stage liver condition, the liver could no more execute vital functions or effectively replace damaged cells.

In this review we will discuss background and etiology of liver cirrhosis, we will emphasize diagnostic methods and management, such as transplantation and lifestyle modification.

2. METHODOLOGY

We conducted an electronic literature search of MEDLINE, EMBASE, and Cochrane Library databases, until December 2017. We used the search Mesh terms: liver cirrhosis, *management, etiology, causes, treatment*. Studies search were restricted to the English language, and human subjects. Furthermore, studies were searched using the references lists of found articles.

3. DISCUSSION

- **Definitions and Etiologies:**

The liver help greatly in the upkeep of metabolic homeostasis by processing nutritional amino acids, carbs, lipids, and vitamins; metabolizing cholesterol and contaminants; producing clotting factors; and storing glycogen. Injury to the liver parenchyma related to an increase of acute or chronic inflammatory cells is called liver disease. Cirrhosis refers to a dynamic, scattered, fibrosing, nodular condition that interrupts the entire regular design of the liver (Table [2], [3]. Fibrosis previously was believed to be an irreversible scarring procedure created in action to inflammation or direct hazardous insult to the liver, yet existing proof suggests that fibrosis might be relatively easy to fix in some patients with chronic hepatitis B after antiretroviral therapy [7].

Any kind of chronic disrespect to the liver could create progression to cirrhosis. Although numerous pathophysiologic mechanisms of injury exist, the last usual pathway is persistent injury recovery resulting in hepatic parenchymal fibrosis. In most individuals, about 80 to 90 percent of the liver parenchyma have to be destroyed prior to liver failing appears clinically. When complications of cirrhosis happen, they usually relate to impaired hepatic function or real physical interruption and reconstruction of the liver parenchyma [2].

TABLE 1. Etiologies of Hepatic Cirrhosis[2],[3].

Most common causes:	**Less common causes:**
Alcohol (60 to 70 percent) Biliary obstruction (5 to 10 percent) Biliary atresia/neonatal hepatitis Congenital biliary cysts Cystic fibrosis Primary or secondary biliary cirrhosis Chronic hepatitis B or C (10 percent) Hemochromatosis (5 to 10 percent) NAFLD (10 percent)—most commonly resulting from obesity; also can occur after jejunoileal bypass	Autoimmune chronic hepatitis types 1, 2, and 3 Drugs and toxins Alpha-methyldopa (Aldomet) Amiodarone (Cordarone) Isoniazid (INH) Methotrexate Oxyphenisatin (Prulet)* Perhexiline* Troglitazone (Rezulin)* Vitamin A Genetic metabolic disease α1-Antitrypsin deficiency Amino acid disorders (e.g., tyrosinemia) Bile acid disorders Carbohydrate disorders (e.g., fructose intolerance, galactosemia, glycogen storage diseases) Lipid disorders (e.g., abetalipoproteinemia) Porphyria Urea cycle defects (e.g., ornithine carbamoyltransferase deficiency) Wilson's disease Idiopathic/miscellaneous Granulomatous liver disease (e.g., sarcoidosis) Idiopathic portal fibrosis Indian childhood cirrhosis Polycystic liver disease Infection Brucellosis Congenital or tertiary syphilis Echinococcosis Schistosomiasis Vascular abnormalities Chronic, passive hepatic congestion caused by right-sided heart failure, pericarditis Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease) Veno-occlusive disease

- **Clinical Presentation:**

HISTORY:

Cirrhosis frequently is a quiet condition, with the majority of patients remaining asymptomatic till decompensation happens. Physicians should ask about threat aspects that incline patients to cirrhosis.Quantity and period of alcohol usage is a crucial variable in the early medical diagnosis of cirrhosis [2].Other risk elements consist of those for hepatitis B and C transmission (e.g., birthplace in native to the island locations, sex-related background exposure danger, intranasal or intravenous substance abuse, body piercing or tattooing, unintentional contamination with blood or body liquids), in addition to transfusion history and personal or family background of autoimmune or hepatic diseases [2].

Early and well-compensated cirrhosis could manifest as anorexia and fat burning, weak point, tiredness, or even weakening of bones as a result of vitamin D malabsorption and succeeding calcium deficiency. Decompensated illness can result in complications such as ascites, spontaneous bacterial peritonitis, hepatic encephalopathy, and variceal blood loss from portal hypertension (reviewed even more in part II [1]. Clinical symptoms at discussion could consist of jaundice of the eyes or skin, pruritus, gastrointestinal blood loss, coagulopathy, enhancing abdominal girth, and mental standing adjustments. Each of these medical findings is the outcome of impaired hepatocellular function with or without physical blockage additional to cirrhosis. Because hepatic enzyme synthesis is required for medicine metabolism, increased sensitivity and medication poisoning might occur in patients with impaired hepatic enzyme synthesis [2], [4].

PHYSICAL EXAMINATION:

Physical examination of patients with cirrhosis might reveal a selection of findings that should bring about a targeted hepatic- or gastrointestinal-based work-up (Table 2) [5]. Several patients will currently have had serologic or radiographic tests or an unconnected operation that incidentally discovered indications of cirrhosis.

TABLE 2. Common Physical Examination Findings in Patients with Cirrhosis[5].

Abdominal wall vascular collaterals (caput medusa)
Ascites
Asterixis
Clubbing and hypertrophic osteoarthropathy
Constitutional symptoms, including anorexia, fatigue, weakness, and weight loss
Cruveilhier-Baumgarten murmur—a venous hum in patients with portal hypertension
Dupuytren's contracture
Fetor hepaticus—a sweet, pungent breath odor
Gynecomastia
Hepatomegaly
Jaundice
Kayser-Fleischer ring—brown-green ring of copper deposit around the cornea, pathognomonic for Wilson's disease
Nail changes:
Muehrcke's nails—paired horizontal white bands separated by normal color
Terry's nails—proximal two thirds of nail plate appears white, whereas the distal one third is red
Palmar erythema
Scleral icterus
Vascular spiders (spider telangiectasias, spider angiomata)
Splenomegaly
Testicular atrophy

The majority of patients with cirrhosis serious enough to bring about ascites have added stigmata of cirrhosis on physical exam. Precisely diagnosing ascites depends upon the quantity of fluid present in the abdomen, the technique utilized to check out the patient, and the patient's habitus. The most helpful physical searching for in validating the presence of ascites is flank monotony to percussion. When this is found, it is handy to establish whether it shifts with rotation of the patient (moving monotony) or whether it could be percussed anteriorly. One research located lack of f lank dullness to be one of the most exact forecaster versus the presence of ascites; the probability of ascites without flank monotony was much less than 10 percent [6]. Approximately 1,500 mL of liquid need to exist prior to dullness is spotted on physical exam, whereas routine ultrasonography can spot as little as 50 mL of fluid in abdominal area [5].

- **Management:**

Abstinence and lifestyle modification:

Attending to the underlying addiction to alcohol is the vital action in managing ALD. Abstinence from alcohol causes resolution of alcoholic fatty liver disease (benign steatosis) and abstaining enhances survival in alcoholic cirrhotic patients, even those with decompensated liver function. Moreover, reducing alcohol intake, yet not entirely stopping, has been shown to enhance survival in patients with ALD [8].While there is no doubt pertaining to the advantage of abstinence, motivating patients to follow this treatment program, monitoring their compliance, and stopping relapse continue to be significant barriers to the treatment of ALD. Definitely, inpatient and outpatient rehabilitation programs have demonstrated effectiveness in helping patients to achieve and keep soberness [9].Reference to and communication with an addiction professional, and motivating energetic participation in Alcoholics Anonymous, represents the most effective method of helping patients with alcoholism and concomitant ALD. While this could not be available to all patients, researches indicate that heavy drinkers who get short interventions (less compared to 1 hour in length and including motivational therapy strategies) are two times as likely as control patients to have changed their alcohol consumption routines 6-12 months after the treatment [10].Acknowledgment and therapy of comorbid psychological problems is likewise a beneficial step in helping patients with alcohol dependence [11].

Various other lifestyle modifications, such as cigarette smoking cessation and weight-loss, if appropriate, are additionally crucial to enhancing the end result of those dealing with ALD. Smoking cigarettes is an independent risk element for improvement of hepatic fibrosis which can result in a lot more severe ALD, and may be linked to the growth of HCC [12].Obesity, which can likewise trigger fatty liver, nonalcoholic steatohepatitis, and cirrhosis, may be an independent danger variable for the progression of ALD [13].

Nutritional support:

It has long been established that patients with ALD (both severe ASH and cirrhosis) are nearly all It has long been established that patients with ALD (both extreme ASH and cirrhosis) are almost all malnourished, and the degree of poor nutrition associates with illness extent [14].Additionally, difficulties of ALD (e.g. infections, encephalopathy, ascites, and variceal blood loss) have been shown to be highly related to protein-calorie lack of nutrition (PCM) [15].Micronutrient shortages of folate, vitamin B6, vitamin A and thiamine are among the most generally experienced. Mineral/element (e.g., selenium, zinc, copper, and magnesium) levels are usually modified in ALD and, in some circumstances, are believed to be associated with its pathogenesis.Specifically, zinc is lowered in patients with ALD. In animal models, zinc supplements has been shown to enhance, undermine, and/or stop ALD with a selection of devices [16].

The spectrum of nutritional problems amongst patients with ALD also covers from somber excessive weight to profound underweight and lack of nutrition. Provided the high calorie content of alcohol (7.1 kcal/g), patients with ALD and concomitant high-calorie diet plans can anticipate to develop truncal excessive weight and resultant development of ALD [15].Offered comparable systems of pathogenesis (e.g., oxidative tension, cyokines, cytochrome P450), patients with the metabolic syndrome/insulin resistance and concomitant ALD would be anticipated to have extra extreme disease with a quicker progression to fibrosis [17].The impact of alcohol on adipokines such as adiponectin is presently under examination [18].With the obesity epidemic handy, the opportunity of concomitant ALD and obesity-related liver illness (including their mixed impact growing incidence of HCC) is, and ought to remain to be, at the center of hepatology study [19] Finally, patients with ALD and obesity are not always immune to the normal nutrient shortages connected with ALD patients that are typical or undernourished.

Pentoxifylline:

The 2010 ACG/AASLD standards for the treatment of serious alcoholic hepatitis (DF $\geq$ 32), advise making use of glucocorticoids as first-line therapy other than in patients with very early kidney failure or clear contraindication to steroids [20].Despite these suggested recommendations, the literary works now sustains making use of PTX, in mix with enteral nutrition, as a sensible option to corticosteroids in patients with extreme ASH.

PTX is a nonselective phosphodiesterase inhibitor that increases intracellular concentrations of adenosine 3 ′,5 ′-cyclic monophosphate (cAMP) and guanosine 3 ′,5 ′-cyclic monophosphate (cGMP). PTX is thought to boost results in alcoholic hepatitis via downregulation of pro-inflammatory cytokines (e.g., TNF-α) that are thought to contribute in the pathogenesis of ASH and are known to be elevated and correlate with condition intensity. PTX has additionally been shown to have antifibrotic effects through the depletion of both profibrogenic cytokine and procollagen I expression [21]. Lastly, based

upon professional data showing a mortality advantage by means of a reduction in the occurrence of hepatorenal disorder (HRS), an advantageous effect on kidney microcirculation and hemodynamics (independent of anti-TNF-α activity) has also been proposed as a mechanism of benefit [22].

A pilot research examining the advantages of PTX in ASH, released in 1991, showed that PTX might minimize mortality and HRS when compared to placebo. The results were then duplicated in a double-blind placebo-controlled trial, which compared the effect of PTX (400 mg orally three times a day for 4 weeks) versus sugar pill in 101 patients with ASH (DF ≥ 32). Patients that received PTX had actually a decreased 28-day mortality compared to those who received placebo (24.5% versus 46%). Notably, of those patients that died during the research, 50% of those in the PTX arm developed HRS, while 91.7% of patients that died in the placebo arm developed HRS [23].An additional study took a look at PTX for patients with ASH who did not reply to corticosteroids (defined by no enhancement in bilirubin after 7 days of therapy). That research study showed no survival advantage from switching over to PTX [24].There have been no tests examining the mix of PTX and corticosteroids in patients that are nonresponsive to corticosteroid treatment (or treatment naïve patients).

Liver transplantation for cirrhosis:

Alcoholic cirrhosis is a leading sign for OLT in North America. Several researches constantly show improved survival in serious ALD, and comparable end results in patients getting liver transplantation for ALD and other etiologies [25].A current situation-control research contrasting lasting end results of OLT in patients with ALD versus liver disease C virus (HCV) infection confirmed 9-year survival rates in patients with ALD is similar to HCV [26].Another current contrast of ALD and HCV as signs for OLT, examined the impacts of ALD and HCV infection on waiting listing death, posttransplant death, and the survival benefit (i.e., liver transplant survival benefit). The research study revealed that the presence of ALD does not affect liver transplant survival advantage [26].Patients grafted for ALD do appear to have a higher incidence of some malignancies adhering to liver transplantation (e.g., upper airway and upper stomach track) [27].Ultimately, lifestyle appears to improve in patients who undergo OLT for ALD and this rate of improvement resembles that connected with other types of liver illness.

Regarding the extent of liver condition and transplantation, a current randomized trial compared instant listing for liver transplantation versus typical care for Child-Pugh phase B alcoholic cirrhosis. The study exposed prompt listing for liver transplantation did disappoint a survival advantage compared to conventional look after Child-Pugh stage B alcoholic cirrhosis. Moreover, there was an increased the danger for extrahepatic cancer in patients in the instant listing arm [28].Notably, other studies have also shown that patients with much more serious condition are more likely to take advantage of OLT [27].

4. CONCLUSION

ALD remains a significant cause of liver related mortality worldwide. Clinicians ought to be experienceded on the diagnosis and treatment of the broad spectrum of hepatologic conditions related to ethanol consumption. Combined with the 2010 AASLD/ACG guidelines on the treatment of serious alcoholic hepatitis, PTX needs to be considered an alternative to corticosteroids and shows up to especially efficient in ALD patients with renal dysfunction/hepatorenal syndrome. Cirrhosis frequently is an indolent disease; most patients continue to be asymptomatic up until the occurrence of decompensation, defined by ascites, spontaneous bacterial peritonitis, hepatic encephalopathy, or variceal bleeding from portal hypertension. Physical examination of patients with cirrhosis may expose a variety of findings that require a hepatic- or gastrointestinal-based work-up to identify the etiology. Transplantation is efficient in patients with end-stage ALD who have stopped drinking (normally for ≥ 6 months), and both lasting graft and patient survival are excellent. Liver transplantation is a sound alternative for carefully picked patients with cirrhosis and alcoholic hepatitis due to the fact that relapse rates are reduced and prognosis is comparable to other etiologies.

REFERENCES

[1] Heidelbaugh JJ, Sherbondy M. Cirrhosis and chronic liver failure. Part II: Complications and treatment. Am Fam Physician. 2006;74:765–74, 779.

[2] Friedman S, Schiano T. Cirrhosis and its sequelae. In: Goldman L, Ausiello D, eds. Cecil Textbook of Medicine. 22nd ed. Philadelphia, Pa.: Saunders, 2004:936–44.

[3] Crawford JM. Liver and biliary tract. In: Kumar V, Abbas AK, Fausto N, eds. Robbins and Cotran Pathologic Basis of Disease. 7th ed. Philadelphia, Pa.: Elsevier Saunders, 2005:877–938.

[4] Diehl A. Alcoholic and nonalcoholic steatohepatitis. Goldman L, Ausiello D, eds. Cecil Textbook of Medicine. 22nd ed. Philadelphia, Pa.: Saunders, 2004:935–6.

[5] Yee HF, Lidofsky SD. Acute liver failure. In: Feldman M, Friedman LS, Sleisenger MH, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 7th ed. Philadelphia, Pa.: Saunders, 2002:1567–74.

[6] Cattau EL Jr, Benjamin SB, Knuff TE, Castell DO. The accuracy of the physical examination in the diagnosis of suspected ascites. *JAMA*. 1982;247:1164–6.

[7] Malekzadeh R, Mohamadnejad M, Rakhshani N, Nasseri-Moghaddam S, Merat S, Tavangar SM, et al. Reversibility of cirrhosis in chronic hepatitis B. Clin Gastroenterol Hepatol. 2004;2:344–7.

[8] Sofair A.N., Barry V., Manos M.M., Thomas A., Zaman A., Terrault N.A., et al. (2010) The epidemiology and clinical characteristics of patients with newly diagnosed alcohol-related liver disease: results from population-based surveillance. J Clin Gastroenterol 44: 301–307.

[9] Miller W.R., Walters S.T., Bennett M.E. (2001) How effective is alcoholism treatment in the United States?J Stud Alcohol 62: 211–220.

[10] Kaner E.F., Dickinson H.O., Beyer F., Pienaar E., Schlesinger C., Campbell F., et al. (2009) The effectiveness of brief alcohol interventions in primary care settings: A systematic review. Drug Alcohol Rev 28: 301–323.

[11] Moos R.H., King M.J., Patterson M.A. (1996) Outcomes of residential treatment of substance abuse in hospital- and community-based programs. Psychiatr Serv 47: 68–74.

[12] Corrao G., Lepore A.R., Torchio P., Valenti M., Galatola G., D'Amicis A., et al. (1994) The effect of drinking coffee and smoking cigarettes on the risk of cirrhosis associated with alcohol consumption. A case–control study. Provincial Group for the Study of Chronic Liver Disease. Eur J Epidemiol 10: 657–664.

[13] Naveau S., Chollet-Martin S., Dharancy S., Mathurin P., Jouet P., Piquet M.A., et al. (2004) A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 39: 1390–1397.

[14] Halsted C.H. (2004) Nutrition and alcoholic liver disease. Semin Liver Dis 24: 289–304.

[15] Stickel F., Hoehn B., Schuppan D., Seitz H.K. (2003) Review article: Nutritional therapy in alcoholic liver disease. Aliment Pharmacol Ther 18: 357–373.

[16] Kang Y.J., Zhou Z. (2005) Zinc prevention and treatment of alcoholic liver disease. Mol Aspects Med 26: 391–404.

[17] Lieber C.S. (2004) CYP2E1: from ASH to NASH. Hepatol Res 28: 1–11.

[18] Yu H.C., Li S.Y., Cao M.F., Jiang X.Y., Feng L., Zhao J.J., et al. (2010) Effects of chronic ethanol consumption on levels of adipokines in visceral adipose tissues and sera of rats. Acta Pharmacol Sin31: 461–469.

[19] Baker S.S., Baker R.D., Liu W., Nowak N.J., Zhu L. (2010) Role of alcohol metabolism in non-alcoholic steatohepatitis. PLoS One 8; 5(3): e9570–e9570.

[20] O'Shea R., McCullough A.J. (2006) Steroids or cocktails for alcoholic hepatitis. J Hepatol 44: 633–636.

[21] Raetsch C., Jia J.D., Boigk G., Bauer M., Hahn E.G., Riecken E.O., et al. (2002) Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis. Gut 50: 241–247.

[22] Assimakopoulos S.F., Thomopoulos K.C., Labropoulou-Karatza C. (2009) Pentoxifylline: a first line treatment option for severe alcoholic hepatitis and hepatorenal syndrome? World J Gastroenterol 15: 3194–3195.

[23] Akriviadis E., Botla R., Briggs W., Han S., Reynolds T., Shakil O. (2000) Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 119: 1637–1648.

[24] Louvet A., Diaz E., Dharancy S., Coevoet H., Texier F., Thevenot T., et al. (2008) Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J Hepatol 48: 465–470.

[25] Day C.P. (2007) Treatment of alcoholic liver disease. Liver Transpl 13(11 Suppl 2): S69–S75.

[26] Biselli M., Gramenzi A., Del Gaudio M., Ravaioli M., Vitale G., Gitto S., et al. (2010) Long term follow-up and outcome of liver transplantation for alcoholic liver disease: a single center case-control study. J Clin Gastroenterol 44: 52–57.

[27] Lucey M.R., Schaubel D.E., Guidinger M.K., Tome S., Merion R.M. (2009b) Effect of alcoholic liver disease and hepatitis C infection on waiting list and posttransplant mortality and transplant survival benefit. Hepatology 50: 400–406.

[28] Neuberger J., Schulz K.H., Day C., Fleig W., Berlakovich G.A., Berenguer M., et al. (2002) Transplantation for alcoholic liver disease. J Hepatol 36: 130–137.

[29] Vanlemmens C., Di Martino V., Milan C., Messner M., Minello A., Duvoux C., et al. (2009) Immediate listing for liver transplantation versus standard care for Child-Pugh stage B alcoholic cirrhosis: a randomized trial. Ann Intern Med 150: 153–161.